The MammaPrint® test analyzes the 70 most important genes associated with breast cancer recurrence. Results are typically available in 6 days or less, MammaPrint enables quicker, more informed decisions on pre- and post-operative treatment and can easily be integrated into diagnostic workups. 1
1 Following the 2016 Publication of MINDACT, the 2017 ASCO guidelines were updated to indicate favorable results in patients with 1-3 positive lymph nodes. MammaPrint’s 510(k) US FDA clearance includes breast cancer patients with Stage 1 or Stage II disease, with tumor size ≤ 5.0 cm and lymph node negative.